Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 13/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.48 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3832837 | 0.83 | MCHR1 (0.60) | MCHR1MLLT1RAB9A | |
| SCHEMBL3833336 | 0.80 | MCHR1 (0.70) | MCHR1RAB9A | |
| SCHEMBL3832829 | 0.79 | MCHR1 (0.59) | MCHR1HDAC8HDAC6RAB9A | |
| SCHEMBL3837599 | 0.78 | MCHR1 (0.57) | MCHR1NAMPTRAB9A | |
| SCHEMBL13817977 | 0.77 | MCHR1 (0.74) | MCHR1RAB9A | |
| SCHEMBL3837969 | 0.76 | MCHR1 (0.68) | MCHR1CYP2C9RAB9A | |
| SCHEMBL3870586 | 0.76 | MCHR1 (0.66) | MCHR1HDAC3HDAC6RAB9A | |
| SCHEMBL13817984 | 0.75 | MCHR1 (0.75) | MCHR1RAB9A | |
| SCHEMBL13818008 | 0.75 | MCHR1 (0.81) | MCHR1RAB9A | |
| SCHEMBL13818000 | 0.75 | MCHR1 (1.00) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553089-B1 | ANTAGONIST OF MELANIN-CONCENTRATING HORMONE RECEPTOR COMPRISING BENZIMIDAZOLE DERIVATIVE AS ACTIVE INGREDIENT | BANYU PHARMA CO LTD (JP) | 2009-09-30 | — | — | EP | disclosed |
| US-7541477-B2 | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-7541477-B2 | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-7541477-B2 | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20050222161-A1 | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient | BANYU PHARMACEUTICAL CO., LTD (JP) | 2005-10-06 | — | — | US | disclosed |
| EP-1553089-A1 | ANTAGONIST OF MELANIN-CONCENTRATING HORMONE RECEPTOR COMPRISING BENZIMIDAZOLE DERIVATIVE AS ACTIVE INGREDIENT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222161-A1 | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient | MC1R, MCHR1, MCHR2 | MCHR1 2/4885CYP2D6 760/4885CYP2C9 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.